Orum Therapeutics, Inc.

KOSDAQ:A475830 Stock Report

Market Cap: ₩771.2b

Orum Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

SJ Lee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure2.8yrs

Recent management updates

No updates

Recent updates

No updates

CEO

SJ Lee

no data

Tenure

Dr. Sung-Joo Lee, also known as SJ, Ph D., is the Founder of Orum Therapeutics, Inc. and serves as Chief Executive Officer and Director. Dr. Lee is Corporate Advisory Board Member at GPCR Therapeutics, Inc...

Leadership Team

NamePositionTenureCompensationOwnership
Sung-Joo Lee
Founderno datano datano data
Martin Intae Jeong
CFO & Director1.4yrsno datano data
Kayla Mo
Head of Investor Relationsno datano datano data
Christopher Martin
Head of Legal3yrsno datano data
Susan Best
Vice President of Global Human Resources3.1yrsno datano data
James Palacino
Head of Research & Senior VP4.4yrsno datano data
Olaf Christensen
Chief Medical Officer3.3yrsno datano data
Greg Dwyer
Head of Business Development3.8yrsno datano data
Rakan Jeong
Controllerno datano datano data
S. H. Choi
Treasurerno datano datano data

3.2yrs

Average Tenure

Experienced Management: A475830's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sung-Joo Lee
Founderno datano datano data
Martin Intae Jeong
CFO & Directorno datano datano data
Peter U. Park
Directorno datano datano data
Sara A. Hurvitz
Member of Scientific Advisory Board2.8yrsno datano data
Roland B. Walter
Member of Scientific Advisory Board2.8yrsno datano data
Maria Koehler
Member of Scientific Advisory Board2.8yrsno datano data
Zoran Rankovic
Member of Scientific Advisory Board2.8yrsno datano data
Jinwoo Jo
Directorno datano datano data

2.8yrs

Average Tenure

Experienced Board: A475830's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 09:33
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Orum Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.